Overview

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Remdesivir (GS-5734™) in Participants From Birth to < 18 Years of Age With Coronavirus Disease 2019 (COVID-19)

Status:
Recruiting

Trial end date:
2022-02-01

Target enrollment:

Participant gender:

Summary

The primary objectives of this study are to evaluate the safety, tolerability, and pharmacokinetics (PK) of remdesivir (RDV) in participants with laboratory-confirmed coronavirus disease 2019 (COVID-19) aged 0 days to < 18 years.

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

Gilead Sciences

Treatments:

Remdesivir